OncoMatch

OncoMatch/Clinical Trials/NCT06562192

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Is NCT06562192 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including [68Ga]Ga-NNS309 and [177Lu]Lu-NNS309 for pancreatic ductal adenocarcinoma.

Phase 1RecruitingNovartis PharmaceuticalsNCT06562192Data as of May 2026

Treatment: [68Ga]Ga-NNS309 · [177Lu]Lu-NNS309 — The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Non-Small Cell Lung Carcinoma

Triple-Negative Breast Cancer

Breast Carcinoma

Colorectal Cancer

Lab requirements

Blood counts

Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L, hemoglobin ≥ 9 g/dL, platelet count ≥ 100 x 10^9/L

Kidney function

Creatinine clearance ≥ 60 mL/min

Cardiac function

QT interval corrected by Fridericia's formula (QTcF) < 470 msec

Absolute neutrophil count (ANC) < 1.5 x 10^9/L, hemoglobin < 9 g/dL, or platelet count < 100 x 10^9/L; QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec; Creatinine clearance < 60 mL/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Uni of Alabama at Birmingham · Birmingham, Alabama
  • University of California LA · Los Angeles, California
  • Stanford University Medical Center · Palo Alto, California
  • Mayo Clinic Jacksonville · Jacksonville, Florida
  • Massachusetts General Hospital · Boston, Massachusetts

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify